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Summary Nasopharyngeal carcinoma is a subset of head and neck squamous cell cancers with unique endemic distribution and aetiological
co-factors. Epstein-Barr virus has been revealed to be an important aetiological factor for most nasopharyngeal carcinomas. Nevertheless,
additional genetic alterations may be involved in their development and progression. The aim of this study was to determine the likely
chromosomal locations of tumour-suppressor genes related to Epstein-Barr virus-associated nasopharyngeal carcinoma. Fifty-six
microsatellite polymorphic markers located on every autosomal arm were used to estimate the incidence of loss of heterozygosity in 27
Epstein-Barr virus-associated nasopharyngeal carcinomas. High frequencies of allelic loss were observed on chromosome 3p (75.0%) and
9p (87.0%). Chromosome 9q, 11q, 13q and 14q displayed loss in over 50%, while chromosome 3q, 6p, 16q, 19q and 22q exhibited loss in
35-50%. Furthermore, several other chromosomal arms demonstrated allelic loss in 20-35%. Additionally, 1 of the 27 cases showed
microsatellite instability at multiple loci. These findings provide evidence of multiple genetic alterations during cancer development and clues
for further studies of tumour-suppressor genes in Epstein-Barr virus-associated nasopharyngeal carcinoma.
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Nasopharyngeal carcinoma (NPC) is a subset of head and neck
squamous cell cancers (HNSCC) with unique endemic distribution
and aetiological co-factors (Fandi et al, 1994). Although NPC is
rare among Caucasians in Europe and North America, it is one of
the most common cancers in southern China and among Eskimos in
Arctic regions, where ithas anincidence of20-50 per 100000 men.
An intermediate incidence is noted in South-East Asia (Voravud,
1990). While HNSCC is closely associated with exposure to
tobacco and alcohol, Epstein-Barr virus (EBV) appears to be an
important aetiological factor for most NPC (Liebowitz, 1994).
Loss of function of tumour-suppressor genes has been impli-
cated as being essential for solid tumour development and related
to chromosomal rearrangement regarding the loss ofnormal chro-
mosomes or segments (Knudson, 1971; Zhu et al, 1992). Various
studies in NPC reported frequent allelic loss on chromosome 3p,
9p and llq and homozygous deletion or hypermethylation of
the p16 gene (Huang et al, 1991; Choi et al, 1993; Lo et al,
1995-1996, Hui et al, 1996). The aim ofthis study was to investi-
gate whether other tumour-suppressor genes are also involved in
NPC development by analysing the loss of heterozygosity (LOH)
on every autosomal arm. Interestingly, allelotyping of HNSCC
have been well characterized (Nawroz et al, 1994; El-Naggar et al,
1995; Field et al, 1995). Allelic loss on chromosome 3p, 9p and
1lq are also frequent events in HNSCC. In addition, frequent LOH
was observed on other chromosomes, e.g. 6p, 8, 13q, 14q, 17p,
18q and 19q (Nawroz et al, 1994; El-Naggar et al, 1995; Field et
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al, 1995). It would be ofgreat interest and importance to elucidate
whether the genetic events in Epstein-Barr virus-associated NPC
are similar or distinct from HNSCC.
MATERIALS AND METHODS
Tissues and DNA extraction
Primary NPC tissues were collected from 27 patients before
treatment at Chulalongkorn University Hospital. The tissues were
divided into two pieces. The first part was sent for routine histo-
logical examination. The second part was immediately stored in
liquid nitrogen until further use. All the tumours were histologi-
cally ascertained to be undifferentiated NPC, according to the
WHO classification. The 27 tumours included stages ranging from
II to IV. Blood samples obtained by venipuncture from the same
patients were used as constitutional controls. DNA was extracted
from the tumour tissues and blood leucocytes by methods previ-
ously described (Maniatis et al, 1989).
EBV detection and typing by PCR
For the detection and typing of EBV DNA in the tumour tissues,
three previously described polymerase chain reaction (PCR)
protocols were used with some modifications (Sample et al, 1990;
Feinmesser et al, 1992; Lin et al, 1993). DNA from cell line B958,
EBV-transformed human lymphocytes (American TIype Culture
Collection), was used as positive control and double-distilled
water as negative control.
Duplex PCR was performed to detect EBV using two sets of
primers. The first amplified the non-polymorphic EBV nuclear
antigen 1 (EBNA-1), generating an approximately 610-bp DNA
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Figure 1 Autoradiographs showing PCR genotyping of EBV-infected NPC
on a 2% agarose gel stained with ethidium bromide. The first lane from the
left is p174 Hae IlIl standard DNA size marker. + and - are PCR products
from positive controls, B958 cell line, and negative controls, double distilled
water, respectively. Numbers indicate corresponding PCR products from NPC
patients. (A) Duplex PCR generating 610-bp and 318-bp DNA fragments for
EBNA-1 and human ,B-actin genomic sequence respectively. (B) PCR
generating 246-bp and 153-bp DNA fragments for EBNA-3C of EBV type B
and type A respectively. (C) PCR generating 184 bp and 168 bp DNA
fragments for EBNA-2 of EBV type B and type A respectively
fragment. The second amplified a human ,-actin genomic
sequence, generating an approximately 318-bp DNA fragment.
The oligonucleotide sequences for both sets of PCR primers were
identical to the ones previously reported (Feinmesser et al, 1992).
Two sets of PCR primers were used for EBV typing. The first
primer amplified the EBV nuclear antigen 2 (EBNA-2), gener-
ating a DNA fragment of 168 bp for EBV type A and of 184 bp for
EBV type B. The second one amplified the EBV nuclear antigen
3C (EBNA-3C), generating a DNA fragment of 153 bp for EBV
type A and of 246 bp for EBV type B. The oligonucleotide
sequences for both sets ofPCR primers were identical to the ones
610 previously reported (Sample et al, 1990; Lin et al, 1993).
The PCR reactions were performed in a total volume of 20 gl
318 using 50 ng of the corresponding tumour DNA in 200 ,UM dNTP
each, 1.5 mM magnesium chloride, 50 mm potassium chloride,
10 mm Tris-HCl (pH 9.0), 0.1% Triton X-100, 0.5 units of
Thermus aquaticus DNA polymerase (Promega) and 0.5 gM of
each primer. The PCR amplifications were performed as follows:
initial denaturation at 94°C for 5 min, followed by 35 cycles of
denaturation at 940C for 30 s, annealing at 57°C for 30 s, with an
extension at 72'C for 1 min and a final extension at 72°C for
7 min. The PCR products were then analysed using 2% agarose
gel electrophoresis.
Allelotyping
Fifty-six microsatellite markers forPCR analysis are listed in Table
1. For each chromosomal arm one to five markers were tested.
One strand ofeach primer pair was end labelled at 37°C for 1-
2 h in a total volume of 10 ,tl containing 10 gM primer, 0.025 mCi
[,y-32P]ATP (Amersham) at 3000 Ci mmol-h, 10 mm magnesium
chloride, 5 mm DTT, 70 mM Tris-HCl (pH 7.6) and 10 units ofT4
polynucleotide kinase (New England Laboratories). Without
further separating of the unincorporated nucleotides, the kinase
reaction was added to the PCR buffer mix.
The PCR reactions were performed in a total volume of 10 ,l
using 50 ng ofgenomic DNA in 200 ,UM dNTP each, 10 mM Tris-
HCl (pH 8.4), 50mm potassium chloride, 1.5 mm magnesium
chloride (for all reactions, except NFl and D20S470, 2.5 and
2.0 mmmagnesium chloride, respectively, was added), 0.5 units of
Thermus aquaticus DNA polymerase (Perkin Elmer Cetus) and
the concentration was calculated from 0.05-0.5 gM ofeachprimer.
The marker sets of (D3S1600, D3S966, D9S169), (DIIS534,
GABRB3, D9S51, DIOS169), (GLUT2, D2S102, TCRD),
(IL2RB, D8S88), (D16S287, D4S174), (D21S258, MFD133,
D20S17, DIS103), (D12S341, D19S221) and (D2S131,
DlOS249) were analysed for LOH using multiplex PCR. The
others were amplified as simplex PCR (Mutirangura et al, 1993).
Several PCRreactions, indicated in parentheses in Table 1, have
been optimized foreach primer set as follows: forreaction 1 and 3,
the initial denaturation step at 95°C for4 min, then followed by 25
cycles of denaturation at 94°C for 1 min, with 1 min of annealing
at 55°C for reaction 1, or 52°C for reaction 3, extension at 72°C
for 2 min and a final extension at 72°C for 7 min; for reaction 2,
the initial denaturation step was 95°C for 4 min, then followed by
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Figure 2 Autoradiographs showing LOH analysis using microsatellite markers. Representative NPC tumours (T) and corresponding normal leucocytes (N) are
shown with microsatellite markers indicated on the bottom. Markers D9S169, D11S897 and D13S284 reveal loss of upper alleles, and markers D3S1038 and
TCRD reveal loss of lower alleles
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Table 1 LOH and MSI data for each locus of 27 NPCs
Locus(C)a Location L/l(%) 11 18 19 24 31 35 38 44 45 47
Stage III IV IV IV R IV II III IV IV
T 3 3 2 4 4 2 2 1 4
N 0 2b 2c 3 3 0 1 2b 2b
M 0 0 0 0 1 0 0 0 0
W HO II II II III 11 III 11 11 11 III
EBV A A A A A A A A A A
D1S243 (1) 1p36.1-2 7/24 (29.2) - - U - + _ + - U -
D1S103 (1) 1q31q32 5/25 (20.0) + + - - - - - - -
D2S131 (3) 2p 2/20 (10.0) - U - - - _ _ _ _
D2S102 (1) 2q33q37 5/22 (22.7) - + - - + - + - U
D3S1038 (3) 3p25 18/24 (75.0) U - U + + + + + U -
D3S192(3) 3p25 U - U + N N + + - -
D3S966 (1) 3p21.3 12/18 (66.6) - U + + + - + U U
D3S1600 (1) 3p14 15/20 (75.0) U - U + + + + - +
GLUT2 (1) 3q26.1-2 11/23 (47.8) U + + - - - + + U
D3S1744(1) 3q23q24 - + U N N - + + N
D4S174 (1) 4p11p15 6/23 (26.1) - - - - _ _ + U -
D4S1554(2) 4q11q35 4/23 (17.4) - U + N - + _ _ _
D5S392 (1) 5p 6/25 (24.0) + - N N - N + _ U N
D5S819 (2) 5p U U - N U - - U U -
D5S82 (1) 5q14q21 7/21 (33.3) - - + + - U + U U
D6S309 (2) 6p 10/21 (47.6) + - + + - U + - +
D6S503(3) 6q 7/22 (31.8) - - - U U + - - - U
D7S517 (1) 7p 4/24 (16.7) - + - - - - + + - -
D7S486(2) 7q31 6/26 (23.1) - - - _ _ - + + - _
NEFL (1) 8p 3/23 (13.0) - - - U _ U + - _ _
D8S88 (1) 8q22 3/22 (13.6) - - - U - - U
D9S169(1) 9p21 20/23 (87.0) + - + + + - + + + +
IFNA (2) 9p22 N - U N N - U + + +
D9S51 (1) 9q 11/22 (50.0) - + + - + U + - - +
ABL1 (1) 9q34 N + + U U U U U U N
D10S249(3) lop 4/21 (21.1) - - - N - - - - - +
D10S169 (1) 10qll.2 3/22 (13.6) U - - N U U - U +
D10S677(1) 10q - N N N - - _ _ _ N
WT1 (1) 11p13 7/25 (28.0) U U + N - - + U + -
D11S554(2) lip - - - N N - U + - -
D11S534(1) 11q13 7/27 (25.9) U - _ N - U - _ U
D11S956(1) 11q13 U - U U N - + _ _ _
INT2 (1) 11q13.3 - - - - - U - U _
D11S976 (1) 11q23 14/26 (53.8) U _ U N N + + + + _
D11S897(2) 11q23 - - - - - U + + + -
D12S341 (2) 12p 7/23 (30.4) - - - + + - U - -
MFD133 (1) 12q 4/20 (20.0) U - - + - _ + _ _
D13S284(2) 13q14.2 14/22 (63.6) N + + + + - + - +
D13S119 (1) 13q14.3-q22 6/20 (30.0) - U + N _ U - + U U
TCRD (1) 14q11.2 10/19 (52.6) - U U U + U U U + _
D14S118 (1) 14q 6/14 (42.9) U + U N - + U + U _
GABRB3 (1) 15qllql3 4/22 (18.2) - - U N - + - - U
D16S287(1) 16p13.11 4/22 (18.2) - U - + + - _ _ _ _
D16S511 (2) 16q22q24 11/23 (47.8) - - - - + + + + U
D17S520(1) 17p12 8/27 (29.6) - - - - - - - - -
D17S1176(2) 17p - - - - - - + - - -
KRT9 (2) 17q21 6/19 (31.6) + U - - - - - - +
D18S59(1) 18p11.2 0/20 (0) U - - - - _ _ _ _ _
D18S35(1) 18q21.2 6/24 (25.0) U U - + - U + - + -
DCC (1) 18q21.1 U _ U + - + U -
D19S221 (2) 19p 9/25 (36) - + - U - - _ + + _
D19S412(2) 19q 2/19 (10.5) U - _ U U - - U _
D20S470(3) 20p 4/20 (20.0) - + - N - U - + U
D20S17(1) 20q12 3/20 (15.0) - - U + _ _ U + _ _
D21S258(1) 21q 3/20 (15.0) - U U U - - - + U _
IL2RB (1) 22q 10/22 (45.5) U - + N + - + _ + _
aC, PCR condition; L, number of positive LOH cases; I, number of informative cases; R, recurrence; A, EBV type A; B,
EBV type B; +, positive LOH result; -, negative LOH result; i, microsatellite instability; U, uninformative result; N, not done.
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IV IV iII IV IV IV IV IV IV iII IV IV IV IV IV IV iII
4 3 3 3 2 4 2 2 3 3 4 4 3 2 3 4 3
0 3 1 3 2a 2c 2b 3 3 0 1 2c 2c 2c 2b 0 0
o o 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
11 III 1111 11 III III III 11 11 III III III III 11III 11
A A A A A A A A B A A A A A A A A
- + - + - - - - - - U + + + - - -
U + + + - - - _ _ _ _ _ _ _ _ _ _
U - - + U - - - - U - + U U - - -
- + U - - - - - U - + - - U - - -
- U + + U + + + + + + U + + U U U
- + + + U + U U + + + + U U + - -
+ + + + - - - U + U - + + U + U N
+ - + + + - - + + + + + + U U U N
U U U U U + - U - + + + - - + - U
- + N - N N N + - U + + - - + - -
+ + + + - - U - + - - U - - - - -
- + U - - - - - - _ _ - + _ _ _ _
U - N - - N + - + - U - + - - - -
- - - - U - U U N U - + + - - - N
U + - - + - - - - - - + + - U - -
- + - - U + - + U U + + - U - - -
- - + U - - - + + - U - + - + + -
- - + - - U - - - U - - U - - - -
- - + U - + - - + - + _ _ _ _ _ _
- - + - U - - - - U - + - - - - -
- - - - + - - - U + - - - + - U -
+ - + U + U U U N U + + + U U U +
+ - + + + U + + + U U + + U + U +
U - - + + - U U - - U U U U U U U
U - + U N U U U U - U - U U U + +
- + + - - - U - N - U U + U - - -
U U U U - U U - + + - U U U U U U
- - N - N - N - + + - U - - N -
U + + - - - U U U U U - U - U U
U N N - - - - + - - - - -
U - U + U U - - - U - - - U U U +
- + + + - - N N - - U + U - +
U - U + + - - - - - - - - U + - +
+ U U + N + N + N - - + U + + - +
U - + U + + - + U - U + - + + - +
+ - + - - + - - N - - N + + - - -
+ - - U - - - U - - U + U - - - U
- + + + + - - U - - U + + + - + U
U - - - - U - - - - - + + + - - +
+ - + + + + - - + + U + U - - - -
U - + + U - + - U - U U U U U U -
_ _ _ _ _ _ _ - - U + + + _ _ _ _
+ + N - U - U - - - - - U - - - -
_ + + _ _ _ _ _ _ + + + + - - U +
- - + + U - - + U U - + + + - - -
- - + + - - - + - + - + + U U - -
- + + + - - - + N U - U U U - U -
- - U - - - - U - U - - - U - U
U - N + + - U - U - - U U U - -
- U - + U - - - N U - U - - U - -
- - + - + - + - - + + + U - - U -
U + - - - + - - - - - - - U - - U
U - + - - - U - - - - - + U - - -
U - + - U - - U - - U - - - - U -
- - + - U + - - U - - - - U - - -
- + + + + + - - U U + - - - - U -
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Figure 3 Frequency of allelic loss for autosome in NPC. Allelotyping was
accomplished using polymorphic microsatellite analysis. The probes used
are listed in Table 1
five cycles ofstep-down PCR denaturation at 94°C for 1 min, with
1 min ofannealing at600C, 590C, 580C, 57°C and 56°C, extension
at 720C for 2 min and 25 cycles ofdenaturation at 940C for 1 min,
annealing at 55°C for 1 min, with extension at 720C for 2 min and
a final extension at 720C for 7 min.
Two microlitres of each reaction were mixed with 1 gl of
formamide-loading buffer, heated at 950C for 2 min, put on ice for
30 s and then loaded onto 6% polyacrylamide/7 M urea gel. DNA
fragments were size fractionated at 70 W until the tracking dye
reached the appropriate point on the gel. After electrophoresis, the
wet gel was transferred to filter paper (Watman), wrapped with
Saran wrap and exposed to Kodak T-mat radiographic film for
6-24 h at-70°C with an intensifying screen.
RESULTS
Twenty-seven EBV-associated NPC samples were selected for
LOH studies. All biopsied specimens were histologically
confirmed. Among these 27 cases, 15 were WHO type II and the
others were WHO type III. Twenty-six cases were infected with
EBV subtype A and one case with type B (Figure 1 and Table 1).
LOH in NPC
A panel of 56 microsatellite polymorphic markers representing
every chromosomal arm was used to screen for LOH frequency.
Table 1 shows the polymorphic loci used to test each chromosomal
arm, patient staging, EBV typing and LOH, as well as microsatel-
lite instability (MSI) results. Results representative for LOH are
shown in Figure 2. Frequencies of LOH for each autosomal arm
are represented in Figure 3.
The frequencies of LOH from each chromosomal arm varied
from 0% to 87%. Chromosome 3p and 9p with 78% and 87%,
respectively, revealed higher incidence than other chromosomal
arms. For chromosome 3p, further analysis displayed that there
were at least two LOH loci, which were 3pl4, D3S1600 and 3p25,
D3S192 and D3S1038. Two cases, 51 and 70, showed LOH from
3p25 but not 3pl4. In contrast, two cases, 47 and 50, revealed loss
from 3pl4 but not 3p25. Two cases, 35 and 93, presented loss from
both 3pl4 and 3p25 but not 3p21. Thus, 3p14 and 3p25 were two
separate LOH loci. Other regions with allelic loss over 50% were
Figure 4 Autoradiograph showing the microsatellite instability at KRT9 and
DCC loci. N, normal DNA; T, tumour DNA
on chromosome 9q (50.0%), llq (53.8%), 13q (63.6%) and 14q
(52.6%). Further analyses of chromosome llq revealed higher
frequency of LOH on llq23 (53.8%), while only 7 out of 27
(25.9%) had LOH on llq13. Additional analyses on chromosome
13 displayed that the incidence of LOH for D13S284, located on
13ql4, was higher than D13S119, located on 13ql4.3-q22. LOH
between 35% and 50% was noted on chromosome 3q (47.8%), 16q
(47.8%), l9p (36.0%) and 22q (45.5%). Finally, several other
chromosomes demonstrated allelic loss in 20-35%.
MSI in NPC
Out of 27 samples tested, MSI for multiple loci was presented in
only one case, i.e. 38. MSI was revealed in 25 of 56 loci. In addi-
tion, sample 93 demonstrated MSI on two loci, DllS956 and
D18S35, and sample 53 showed MSI on one locus, D11S956.
Representative results for MSI are shown in Figure 4. No signifi-
cant clinical difference was noted regarding these cases.
DISCUSSION
Several areas ofchromosomal loss during cancer development and
progression are associated with inactivation of both tumour-
suppressor gene alleles (Huang et al, 1991; Zhu et al, 1992; Nawroz
et al, 1994). In addition, they are correlated with the histopathology,
staging and clinical outcome of cancer (Broder et al, 1995). Here
we demonstrated several chromosomes with significant LOH in
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NPC. While several LOH loci are common to HNSCC, some
appear to be unique to NPC progression.
Previously Choi et al (1993) showed LOH on chromosome 3p
for all of the informative 35 NPC cases and Huang et al (1994)
studied chromosome 9p and found allelic loss on11 samples from
18 NPC. Consistently, in this study, two of the highest incidences
of allelic loss have been shown on chromosomes 3p (78%) and 9p
(87%). Three LOH loci have been reported on chromosomes 3p,
3pl4, 3p2l and 3p25 (Maestro et al, 1993). This study revealed
that, at least, the 3pl4 and 3p25 loci are associated with NPC
development. It should also be noted that a putative tumour-
suppressor gene, VHL, is the candidate gene on chromosome 3p25
(Latif et al, 1993). For 9p, the LOH locus has been defined on
chromosome band 9p21; and gene pl6, which controls cell cycles,
has previously been shown to have homozygous deletion or hyper-
methylation (Lo et al, 1995, 1996). Interestingly, 9p LOH has now
been well documented in precancerous lesions of HNSCC (El-
Naggar et al, 1995). It is interesting to investigate whether genetic
alterations of chromosome 9p might also be an early event ofNPC
carcinogenesis.
Allelic loss of chromosome 1 lq has been observed in several
other tumour types, such as HNSCC, breast, ovary and lung
(Nawroz et al, 1994; Gudmundsson et al, 1995a; lizuka et al,
1995). Poor prognosis of breast and ovarian cancer has been asso-
ciated with 11qLOH (Gudmundsson et al, 1995a). At least three
LOH loci have been delineated on chromosome 1lq, 1 1q13, 1 1q15
and 1 1q23 (Iizuka et al, 1995). In addition, 1 1q13 is a chromosome
region with a high frequency of amplification in HNSCC
(Meredith et al, 1995). This results in allelic imbalance and may be
difficult to distinguish from LOH. This study described a higher
frequency of allelic loss in NPC on 11q23 than on 1 1q13. It should
also be noted that the LOH on 11q23 may be related to the ataxia-
telangiectasia locus (Savitsky et al, 1995).
Chromosome 13qLOH is also frequently detected in several
cancers, such as retinoblastoma, breast cancer and HNSCC (Zhu et
al, 1992; Nawroz et al, 1994; Gudmundsson et al, 1995b). This
study has shown that the common LOH locus in NPC may be
located proximal to 13ql4.3. At least two tumour-suppressor
genes are located proximal to this region. The first is Rb,
retinoblastoma gene, and the other is BRCA2, the candidate gene
for the second locus ofthe familial breast cancer syndrome (Zhu et
al, 1992; Gudmundsson et al, 1995b). Previous mutation analysis
of Rb on NPC demonstrated negative results (Sun et al, 1993).
Thus, it is tempting to hypothesize that the BRCA2 tumour-
suppressor gene may be responsible for NPC development.
The allelic loss of chromosome 14q was also frequently found
in other types of cancer, e.g. bladder cancer, neuroblastoma,
colorectal cancer and HNSCC (Fong et al, 1992; Young et al,
1993; Nawroz et al, 1994; Chang et al, 1995). A recent study has
delineated two tumour-suppressor gene loci on chromosome 14,
i.e. 14ql2 and 14q32 (Chang et al, 1995). Interestingly, LOH of
14q is associated with an advanced phenotype of neuroblastoma
and frequently found in advanced colorectal cancer (Fong et al,
1992; Young et al, 1993).
Chromosome 17p is one of the most common regions with
genetic alterations reported in cancer. p53, the best known tumour-
suppressor gene, is located on this chromosome (Carson et al,
1995). p53 alterations, including protein expression and muta-
tions, are common in HNSCC while mutation of p53 in NPC is
infrequent (Field et al, 1991; Boyle et al, 1993; Shin et al, 1994;
Brennan et al, 1995; Chakrani et al, 1995). The LOH study ofthis
chromosome supported the mutation data in which allelic loss of
chromosome 17p was noticed in only 30% of the NPC, while
previous reports revealed 50% LOH of the HNSCC (Nawroz et al,
1994; Field et al, 1995).
Among 27 cases tested, 15 were WHO type II and 12 were
WHO type III. The average frequencies of LOH for each chromo-
some region were 0.34 and 0.31 for WHO type II and III respec-
tively. Interestingly, LOH was found to be more frequent on
chromosome 4p, 7p, 9q, 1 q and 22q for WHO type II, while a
higher frequency of LOH forWHO type III was reported on chro-
mosome 6p and l5q. However, because of the limited number of
tumours, these comparative data are not statistically significant.
MSI is presented as variations in the length of microsatellite
repeats in tumour DNA when compared with matched normal
DNA. The abnormality in the size of the microsatellite loci has
been observed in various types of cancer as well as in hereditary
non-polyposis colorectal cancer (HNPCC) (Thibodeau et al,
1993). In HNPCC, mutations in a number of DNA mismatch
repair genes (hMSH2, hMLH1, hPMSJ and hPMS2) have been
reported. Thus, MSI may be the consequence of decreased accu-
racy of the DNA mismatch repair system during DNA replication,
which might facilitate the accumulation of mutations (Rhyu,
1996). This study has presented MSI of multiple loci in only one
out of 27 NPC samples tested. This suggests that the phenomenon
of MSI is a relatively rare event during NPC development.
NPC is a unique subclassification of HNSCC as a result of its
endemic distribution and aetiological cofactors. It would be of
great interest and importance to elucidate whether the genetic
events in Epstein-Barr virus-associated NPC are similar or distinct
from HNSCC. Previous HNSCC studies have demonstrated a high
frequency of LOH on chromosomes 3p, 3q, 6p, 8p, 8q, 9p, 1lq,
13q, 14q, 17p, 18q and 19q (Nawroz et al, 1994; El-Naggar et al,
1995; Field et al, 1995). Nawroz et al (1994) studied 29 HNSCCs
and showed 67, 50, 38, 40, 38, 72, 61, 54, 39, 52, 23 and 40%
allelic losses respectively. Additionally, Field et al (1995) tested
80 specimens and found LOH more frequently on chromosome 3p,
8p, 9p, 13q, 17p, 18q and 19q for 52, 35, 62, 27, 50, 49 and 29%
respectively. Finally, El-Naggar et al (1995) studied 20 patients for
LOH on chromosome 3p, Sq, 8p, 9p, 9q, llq and 17p, and a high
incidence of LOH in invasive carcinoma was observed at 9p
(72%), 8p (53%), 3p (47%), 9q (35%) and llq (33%). Similar
incidences on chromosomes 3p (78%), 3q (48%), 6p (48%), 9p
(87%), llq (54%), 13q (64%) and 14q (43%) have also been
detected regarding NPC. However, NPC revealed lower inci-
dences of LOH on chromosomes 8p (13%), 17p (30%) and 19q
(11%). In contrast, this study has shown frequent allelic loss
regarding NPC on chromosomes 16q (48%) and 22q (46%). As
several genetic alterations of NPC and HNSCC are similar, the
multistep processes for the development and progression of both
cancers overlap. However, some genetic changes seem to be
unique in the biology of NPC development.
It would also be of interest to compare these allelotyping data
with the allelic loss pattern of other EBV-associated neoplasias,
for example post-immunosuppression/transplant, AIDS-related
and Burkitt's lymphomas. However, there is only limited knowl-
edge of LOH for comparison at present.
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